Conference Agenda – 29 October 2025
Time
Title
Speakers
08:15–09:00
Registration and Welcome Coffee
09:00–09:05
Opening Remarks from Novartis
.-
09:00–09:05
Welcome and Introduction
Valeria De Luca, Novartis (Chair)
Session 1:
AI in Clinical Development
09:05–09:10
Introduction to Session 1
Moderator
Valeria De Luca
09:10–09:30
Keynote
Connected Intelligence: How AI is Reshaping Development Across the Ecosystem
Maxwell Lawson, Novartis
09:30–09:50
Delivering Value with Generative AI – A Real World Example of Digital Transformation
Waheed Jowiya and Louisa Lind Skov, Novo Nordisk
09:50–10:10
Owkin's AI & Agents to Support Decision-Making in Early Drug Development
Jonas Béal, Owkin
10:10–10:30
Panel and Q&A
Moderator: Valeria De Luca
Panel: Maxwell Lawson, Waheed Jowiya, Lousie Lind Skov
and Eric Durand
10:30–11:00
Networking Break
Session 2:
AI to Scale Precision Medicine
11:00–11:05
Introduction to Session 2
Moderator: Jelena Curcic, Novartis
11:05–11:25
From Models to Medicine: Theoretical Foundations and Practical Impact of Machine Learning in Healthcare
Julia Vogt, ETH
11:25–11:45
Nikhil Reddy Podduturi, Boehringer Ingelheim
11:45–12:05
Advanced Patient-Level Insights Generation Using AI in Early Clinical Development
Jörg Degen, Roche
12:05–12:35
Panel and Q&A
Panel and Q&A Moderator: Jelena Curcic, Panel: Julia Vogt, Jörg Degen and Nikhil Reddy Podduturi
12:35–13:35
Networking Break – Lunch
Session 3:
Event Partner Session
13:35–13:50
Digitised Protocol Drives Value Creation for Clinical Teams– Learnings and Best Practices from Success Stories
Jiajie Zhang, Evinova
13:50–14:05
AI-Powered Clinical Trials: Accelerating Pharma Innovation with AWS
Boris Bogdan, Amazon Web Services
14:05–14:20
From Molecule to Market: Transforming Clinical Development and Clinical Operations with AI
Raja Shankar, IQVIA
14:20–14:35
From Tool to Teammate: Unleashing the Power of Agentic AI
Andrew MacKinnon, Medable
14:35–15:00
Networking Break
Session 4: Lightning Talks
AI in Clinical Trials: Regulatory Success Stories
15:00–15:05
Introduction to Session 3
Moderator: Alette Hunt, Novartis
15:05–15:20
AI Policy: What Does It Mean for Clinical Trials?
Thomas Brookland, Roche
15:20–15:35
Implementing GenAI in Regulatory Affairs: a Bayer Experience
Paul Bolot, Bayer
15:35–15:50
Transforming Regulatory Activities with AI
Rebecca Lumsden, Sanofi
15:50–16:20
Panel and Q&A
Moderator: Alette Hunt
Panel: Thomas Brookland, Paul Bolot, Rebecca Lumsden
16:20–16:30
Closing Remarks
Maxwell Lawson, Novartis
16:30–17:30
Networking Apéro
18:00–21:30
Dinner at Basso. (Separate ticket to entry needed)
Venue
29–10–2025